Plus, news on Antabio’s €25 million Series B, Athira’s Alzheimer’s data, Connect’s asthma results and Liquidia’s $25 million raise.
ETheRNA announced Tuesday that it raised $39 million in a Series B2 round, securing two big-name investors: Moderna co-founder Kenneth Chien and ex-Bayer and Thermo Fisher CEO Marijn Dekkers. Both of them are joining the biotech’s board of directors, according to a statement.
GENT, Belgium, April 05, 2022 (GLOBE NEWSWIRE) -- eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is...
Specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, eTheRNA Manufacturing, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.
NIEL, Belgium, March 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid...
NIEL, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today...
eTheRNA immunotherapies NV, a company develops immunotherapy and vaccine products, announced the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a research agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany.
 eTheRNA immunotherapies NV ('eTheRNA' or the 'Company'), a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, today announces the opening of its new subsidiary, eTheRNA Asia Limited ('eTheRNA Asia'), with offices located in the Sheung Wan area of Hong Kong.
eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.